BACKGROUND: IgA nephropathy (IgAN) is the most common glomerulonephritis, which may also coexist with other diseases. We present two patients with an unusual coincidence of IgAN and Fabry disease (FD). CASE PRESENTATION: A 26 year-old man underwent a renal biopsy in February 2001. Histopathology showed very advanced IgAN and vascular changes as a result of hypertension. Because of his progressive renal insufficiency the patient began hemodialysis in August 2001. By means of the blood spot test screening method the diagnosis of FD was suspected. Low activity of alpha-galactosidase A in the patient's plasma and leukocytes and DNA analysis confirmed the diagnosis of FD. Enzyme replacement therapy started in July 2004. Then the patient underwent kidney transplantation in November 2005. Currently, his actual serum creatinine level is 250 μmol/l. Other organ damages included hypertrophic cardiomyopathy, neuropathic pain and febrile crisis. After enzyme replacement therapy, myocardial hypertrophy has stabilized and other symptoms have disappeared. No further progression of the disease has been noted.The other patient, a 30 year-old woman, suffered from long-term hematuria with a good renal function. Recently, proteinuria (2.6 g/day) appeared and a renal biopsy was performed. Histopathology showed IgAN with remarkably enlarged podocytes. A combination of IgAN and a high suspicion of FD was diagnosed. Electron microscopy revealed dense deposits in paramesangial areas typical for IgAN and podocytes with inclusive zebra bodies and myelin figures characteristic of FD. FD was confirmed by the decreased alpha-galactosidase A activity in plasma and leukocytes and by DNA and RNA analysis. Enzyme replacement therapy and family screening were initiated. CONCLUSIONS: Our results emphasize the role of complexity in the process of diagnostic evaluation of kidney biopsy samples. Electron microscopy represents an integral part of histopathology, and genetic analysis plays a more and more important role in the final diagnosis, which is followed by causal treatment.

Department of Nephrology Charles University Prague Czech Republic

See more in PubMed

Johnson JR, John Feehally J. IgA nephropathy and Henoch-Schonlein Nephritis. Clin Nephrol. 2003;24:319–329.

Whybra C, Schwarting A, Kriegsmann J, Gal A, Mengel E, Kampmann C, Baehner F, Schaefer E, Beck M. IgA nephropathy in two adolescent sisters heterozygous for Fabry disease. Pediatr Nephrol. 2006;21:1251–1256. doi: 10.1007/s00467-006-0176-5. PubMed DOI

Poupětová H, Ledvinová J, Berná L, Dvořáková L, Kožich V, Elleder M. The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations. J Inherit Metab Dis. 2010;33:387–396. doi: 10.1007/s10545-010-9093-7. PubMed DOI PMC

Merta M, Reiterova J, Ledvinova J, Poupetová H, Dobrovolny R, Rysavá R, Maixnerová D, Bultas J, Motán J, Slivkova J, Sobotova D, Smrzova J, Tesar V. A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population. Nephrol Dial Transplant. 2007;22(1):179–186. PubMed

Shabbeer J, Yasuda M, Luca E, Desnick RJ. Fabry disease: 45 novel mutations in the alpha-galactosidase A gene causing the classical phenotype. Mol Genet Metab. 2002;76(1):23–30. doi: 10.1016/S1096-7192(02)00012-4. PubMed DOI

Donadio JV, Bergstralh EJ, Grande JP, Rademcher DM. Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy. Nephrol Dial Transplant. 2002;17:1197–1203. doi: 10.1093/ndt/17.7.1197. PubMed DOI

D’Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol. 2004;24:179–196. doi: 10.1016/j.semnephrol.2004.01.001. PubMed DOI

Dobrovolny R, Dvořákova L, Ledvinová J, Magage S, Bultas J, Lubanda JC, Elleder M, Karetova D, Pavlíková M, Hřebíček M. Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population. J Mol Med. 2005;83:647–654. doi: 10.1007/s00109-005-0656-2. PubMed DOI

Martinez AN, Hernandez BFJ, Martin PG. Fabry’s disease associated with rheumatoid arthritis. Multisystemic crossroads. An Med Interna. 2003;20:28–30. PubMed

Martinez P, Aggio M, Rozenfeld P. High incidence of autoantibodies in Fabry disease patients. J Inherit Metab Dis. 2007;30:365–369. doi: 10.1007/s10545-007-0513-2. PubMed DOI

Majima K, Ishizaki T, Inoue T, Hori Y, Egami J, Oohara A, Nishida H, Miyake Y, Matsumoto S, Kinoshita E. A case of Fabry’s disease associated with lupus nephritis. Nihon Jinzo Gakkai Shi. 1992;34:1189–1194. PubMed

Rahman P, Gladman DD, Wither J, Silver MD. Coexistence of Fabry’s disease and systemic lupus erythematosus. Clin Exp Rheumatol. 1998;16:475–478. PubMed

Rosenmann E, Kobrin I, Cohen T. Kidney involvement in systemic lupus erythematosus and Fabry’s disease. Nephron. 1983;34:180–184. doi: 10.1159/000183006. PubMed DOI

Knol IE, Ausems MG, Lindhout D. et al.Different phenotypic expression in relatives with fabry disease caused by a W226X mutation. Am J Med Genet. 1999;82:436–439. doi: 10.1002/(SICI)1096-8628(19990219)82:5<436::AID-AJMG14>3.0.CO;2-X. PubMed DOI

Tumer L, Ezgu FS, Hasanoglu A, Dalgic B, Bakkaloglu SA, Memis L, Dursun A. The co-existence of Fabry and celiac diseases:a case report. Pediatr Nephrol. 2004;19:679–681. doi: 10.1007/s00467-004-1462-8. PubMed DOI

Hiraizumi Y, Kanoh M, Shigematsu H, Yamashina M, Kondo T. A case of Fabry’s disease with granulomatous interstitial nephritis. Nippon Jinzo Gakkai Shi. 1995;37:655–661. PubMed

Van Loo A, Vanholder R, Madsen K, Praet M, Kint J, De Paepe A, Messiaen L, Lameire N, Hasholt L, Sorensen SA, Ringoir S. Novel frameshift mutation in a heterozygous woman with Fabry disease and end-stage renal failure. Am J Nephrol. 1996;16:352–357. doi: 10.1159/000169023. PubMed DOI

Singh HK, Nickeleit V, Kriegsmann J, Harris AA, Jennette JC, Mihatsch MJ. Coexistence of Fabry’s disease and necrotizing and crescentic glomerulonephritis. Clin Nephrol. 2001;55:73–79. PubMed

Yoshida A, Morozumi K, Takeda A, Koyama K, Oikawa T. Fabry-like laminated myelin body associated with IgA nephropathy. Nippon Jinzo Gakkai Shi. 1994;36:1303–1307. PubMed

Pisani A, Sessa A, Sabbatini M, Andreucci MV, Fusco C, Balletta M, Cianciaruso B. Fabry nephropathy in a female with superposed IgA glomerulonephritis. G Ital Nefrol. 2005;22:385–389. PubMed

Kakita T, Nagatoya K, Mori T. Coincidental finding of Fabry’s disease in a patient with IgA nephropathy. NDT Plus. 2010;3:443–446. doi: 10.1093/ndtplus/sfq108. PubMed DOI PMC

Kawamura O, Sakuraba H, Itoh K, Suzuki Y, Doi M, Kuwabara H, Oshima S, Abe S, Warabi H, Yoshizawa N. Subclinical Fabry’s disease occurring in the context of IgA nephropathy. Clin Nephrol. 1997;47:71–75. PubMed

Shimohata H, Yoh K, Takada K, Tanaka H, Usui J, Hirayama K, Kobayashi M, Yamagata K. Hemizygous Fabry disease associated with IgA nephropathy: a case report. J Nephrol. 2009;22(5):682–684. PubMed

Kiryluk K, Julian BA, Wyatt RJ, Scolari F, Zhang H, Novak J, Gharavi AG. Genetic studies of IgA nephropathy: past, present, and future. Pediatr Nephrol. 2010;25(11):2257–2268. doi: 10.1007/s00467-010-1500-7. PubMed DOI PMC

Hall YN, Fuentes EF, Chertow GM, Olson JL. Race/ethnicity and disease severity in IgA nephropathy. BMC Nephrol. 2004;5:10,2369. PubMed PMC

Novak J, Vu HL, Novak L, Julian BA, Mestecky J, Tomana M. Interactions of human mesangial cells with IgA and IgA-containing circulating immune complexes. Kidney Int. 2002;62:465–475. doi: 10.1046/j.1523-1755.2002.00477.x. PubMed DOI

Novak J, Tomana M, Matousovic K, Brown R, Hall S, Novak L, Julian BA, Wyatt RJ, Mestecky J. IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int. 2005;67:504–513. doi: 10.1111/j.1523-1755.2005.67107.x. PubMed DOI

Schena FP. For further infestigations in IgA nephropathy the approach from phenotype to genotype is welcome. Clin Exp Immunol. 2002;127:399–401. doi: 10.1046/j.1365-2249.2002.01821.x. PubMed DOI PMC

Kiryluk K, Li Y, Sanna-Cherchi S, Rohanizadegan M, Suzuki H, Eitner F, Snyder HJ, Choi M, Hou P, Scolari F, Izzi C, Gigante M, Gesualdo L, Savoldi S, Amoroso A, Cusi D, Zamboli P, Julian BA, Novak J, Wyatt RJ, Mucha K, Perola M, Kristiansson K, Viktorin A, Magnusson PK, Thorleifsson G, Thorsteinsdottir U, Stefansson K, Boland A, Metzger M, Thibaudin L, Wanner C, Jager KJ, Goto S, Maixnerova D, Karnib HH, Nagy J, Panzer U, Xie J, Chen N, Tesar V, Narita I, Berthoux F, Floege J, Stengel B, Zhang H, Lifton RP, Gharavi AG. Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet. 2012;8(6):e1002765. doi: 10.1371/journal.pgen.1002765. Epub 2012 Jun 21. PubMed DOI PMC

Hamers MN, Donker-Koopman WE, Coulon-Morelec MJ, Dupouey P, Tager JM. Characterization of antibodies against ceramidetrihexoside and globoside. Immunochemistry. 1978;15(6):353–358. doi: 10.1016/0161-5890(78)90130-X. PubMed DOI

Desnick RJ, Sweeley CC. In: The Metabolic Basis of Inherited Disease. 5th. Stanbury JB, Wyngaarden JB, Fredrickson DS, Goldstein JL, Brown MS, editor. NY: McGraw-Hill; 1983. Fabry’s disease:α-galactosidase A deficiency; pp. 906–944.

Shibata S, Takeda T, Natori Y. The structure of nephritogenoside:a nephritogenic glycopeptide with α-N-glycosidic linkage. J Biol Chem. 1988;263:12483–12485. PubMed

Desnick RJ, Joannou YA, Eng CM. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, Valle D, editor. New York, USA: McGraw-Hill; 2001. α-galactosidase A deficiency: Fabry Disease; pp. 3733–3774.

Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Störk S, Voelker W, Ertl G, Wanner C, Strotmann J. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy:evidence for a better outcome with early treatment. Circulation. 2009;119:524–529. doi: 10.1161/CIRCULATIONAHA.108.794529. PubMed DOI

Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C. Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int. 2006;69:1216–1221. doi: 10.1038/sj.ki.5000208. PubMed DOI

The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts